CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study, GLP-1-H24-2, in July. A three-arm, crossover investigation that compares three 7 mg semaglutide dose formulations, the study evaluates three doses: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsule; and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. The study is designed to measure tolerability and side effects as well as semaglutide and blood glucose levels. Rybelsus (semaglutide) is the only GLP-1 drug approved by the FDA for oral dosingto treat diabetes and weight loss. “Blood samples will be taken multiple times during the first 10 hours post dosing,” the company stated in the press release. “A final blood draw will be taken 24 hours after dosing, and a standardized meal will be fed to the test subjects at a point in time after dosing. Nine healthy subjects are expected to be dosed with each test article with roughly a 30-day ‘washout’ interval between each dosing visit.

To view the full press release, visit https://cnw.fm/BZSDc

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 43 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Adolescents’ Use of Marijuana Heightens Psychotic Disorders Risk

A recent study featured in the “Psychological Medicine” journal delves into the relationship between adolescent marijuana use and the development of psychotic disorders. The research indicates a significant increase in psychotic disorder risks during adolescence linked to marijuana use, a risk that is particularly pronounced with the stronger marijuana products available today. Interestingly, this increased risk does not extend into young adulthood.

Previous studies have suggested a link between youth marijuana use and psychotic disorders, noting a higher likelihood of such disorders among marijuana users. These earlier studies often relied on outdated data when marijuana was less potent and faced limitations such as small sample sizes and less clinically significant outcomes.

The recent study assessed the relationship between teenage marijuana usage and the likelihood of receiving a clinical diagnosis of a psychotic condition using more recent population-based statistics. The goal of the research was to bring the findings up to speed with the current increase in marijuana potency.

Data were drawn from the Canadian Community Health Survey (CCHS) between 2009 and 2012, linked with Ontario’s administrative health records. The study focused on Ontario residents aged 12 to 24 years of age. Those with incomplete medical records or a history of psychotic disorders were excluded, resulting in a final sample of 11,363 participants.

Information on marijuana use and other substance usage, along with sociodemographic details was collected through interviews conducted both by phone and in person. The follow-up ended in 2018 after a maximum of nine years of monitoring the participants. The analysis accounted for various confounding factors, including sex, age, race, other drug use and income.

Approximately 23.4% of respondents reported using marijuana in the past 12 months, and during the follow-up, 1.2% sought healthcare for psychotic disorders. The analysis revealed a significant association between psychotic disorders and recent marijuana use among adolescents aged 12 to 19 years of age, with an adjusted hazard ratio of 11.21. This was not found in young adults aged 20 to 33 years of age, who had an aHR of 1.29.

Subsequent analysis supported these results, demonstrating an aHR of 26.68 for adolescent cannabis users’ hospitalizations or doctor visits linked to psychotic illnesses. Additionally, a dose-response association was noted, with an aHR of 10.70 indicating that frequent marijuana use among teenagers was associated with a higher risk. An analysis focusing on gender revealed that this link, with an aHR of 9.98, was significant for teenage males.

Additionally, the study discovered a substantial correlation between cannabis usage in the year prior and the utilization of healthcare services for psychotic disorders in the past, indicating a possible reverse causal relationship.

The study’s strengths include the use of representative and high-quality data from the CCHS and linked health records, as well as a validated outcome measure and recent cannabis potency data. However, limitations include a single baseline assessment, self-reported marijuana use, and possible unmeasured confounding measures including family history, trauma and genetic predispositions.

These findings hold important implications for public policy and health, especially concerning the prevention of teenage marijuana use.

This elevated risk of adolescents developing psychosis when they use marijuana makes a strong case for allowing legal marijuana sales by licensed companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) in states because guardrails, including verifying the age of a product buyer, can be implemented to make it harder for teens to access marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Completes Strategic Acquisition

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced the successful completion of its acquisition of Cargo Management Group, a reputable and longstanding shipping, logistics and trucking operation, from TK Zarro, LLC. The acquisition marks a significant milestone in GTV’s expansion efforts, as well as enhancing its operational capabilities within its Lavish Entertainment division and providing a full suite of in-house logistics capabilities for other company operations. Cargo Management Group reported nearly $3 million in revenue for 2023 and brings a robust portfolio of contracts with industry leaders such as JB Hunt, CH Robinson, Coyote Logistics, and Echo Logistics. “The acquisition of Cargo Management Group is a transformative step for GTV. This deal provides a scalable business model that will support both Lavish Entertainment and the development of our future flagship project, Destino Ranch,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “This business, its income, and our recently completed renegotiations on our outstanding note will dramatically impact our balance in a positive manner. Additionally, this helps move GTV toward its goal of becoming a highly profitable company with minimal to zero debt and a diverse asset portfolio.”

To view the full press release, visit https://cnw.fm/xlWw2

About Golden Triangle Ventures Inc. (“GTV”)

Golden Triangle Ventures is a multifaceted consulting company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors, along with others that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which this company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the company. An amazing team of professionals support each division and continue to help the company grow daily. Being a publicly traded company gives the ability to provide the support needed to help each subsidiary grow into the business that management believes it can and will become. For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Police Groups Support Bill to Authorize Cannabis Interstate Commerce, End Federal Prohibition in States

A bipartisan initiative aiming at terminating federal enforcement of marijuana laws in states where it is legal has the backing of two significant law enforcement organizations: the Oregon Coalition of Police and Sheriffs (ORCOPS) and the Peace Officers Research Association of California (PORAC). The huge tobacco and alcohol businesses are among the members of the Coalition for Cannabis Policy, Education, and Regulation (CPEAR), which made this endorsement announcement.

The bill, known as the STATES 2.0 Act, has gained backing from prominent lawmakers, including Representative Dave Joyce, the primary sponsor. Joyce, a former prosecutor, expressed gratitude toward the law enforcement associations for their support, emphasizing the inefficiency and counterproductive nature of forcing officers to navigate conflicting state and federal cannabis laws. He highlighted that this bill would resolve these discrepancies, allowing law enforcement to better focus on public-safety and community-specific needs.

Other sponsors of the bill include Representatives Brian Mast, Troy Carter, Lori Chavez-DeRemer and Earl Blumenauer. The proposed legislation seeks to amend the CSA, thereby decriminalizing federal offenses for individuals complying with state marijuana laws and those of Indian tribes. It also aims to authorize interstate cannabis commerce and proposes a tax on marijuana to support enforcement and regulation efforts.

Brian Marvel, president of PORAC, praised the STATES 2.0 Act, noting its balance between federal oversight and state autonomy. He emphasized that while state-level legalization does not eliminate illegal markets, the act would help law enforcement target those markets more effectively. This would enable understaffed and underfunded agencies to allocate resources toward more serious crimes and illegal substances.

ORCOPS president Aaron Schmautz underscored the importance of state and federal cooperation in ensuring laws and policies achieve their intended outcomes. He highlighted the longstanding disconnect between federal marijuana regulations and state legalization efforts, affirming that the STATES 2.0 Act addresses this issue and promotes public safety and responsible marijuana policies nationwide.

Additionally, the bill includes provisions to remove cannabis sales subject to state regulation from Section 280E of the IRS code, which now prohibits the industry from claiming federal tax deductions that are available to other markets. Following the bill’s passage, the attorney general would have six months to complete a rule modifying the CSA to exempt states and tribes from the federal government’s prohibition on cannabis use.

Former Representative Greg Walden, cochair of CPEAR, emphasized the bill’s respect for state rights and its potential to resolve conflicts arising from outdated federal policies. Walden, whose views on cannabis policy evolved during his time in Congress, now advocates for aligning federal laws with state regulations, reflecting the will of voters and supporting law enforcement.

The executive director of CPEAR, Andrew Freedman, praised the STATES Act for encouraging reasonable drug-policy reform and coordinating federal policy with state initiatives. He emphasized the necessity of laws that safeguard children, improve traffic safety, fight addiction and honor local marijuana laws.

Additionally, CPEAR emphasized a recent survey that found more than 60% of Republicans are in favor of congressional legislation that preserves states’ autonomy to enact cannabis regulations. The bipartisan appeal of the STATES 2.0 Act is highlighted by this broad support.

The momentum in favor of federal marijuana policy reform is growing, and marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) can believe that change is likely to come sooner rather than later.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

10th Annual CWCBExpo To Witness Major Players Discussing Key Market Trends

The CWCBExpo is an essential B2B expo on the East Coast, being held at the Javits Convention Center in New York City. This year the Expo will be held from June 5-6, 2024, for two days of networking and engaging educational sessions.

The event schedule is meticulously planned as follows:

June 4, 2024 – The exhibitors set up their booths, the pre-workshops are conducted on cultivation and operating a dispensary, and attendees can connect with industry colleagues at the rooftop bash that night.
June 5, 2024 – After the registration and the media and press preview, the expo commences with a ribbon-cutting event. The expo floor opens and conference programs are conducted.
June 6, 2024 – The attendees can participate in the conference programs and visit the expo on both the days. Along with business and networking, the participants can unwind, enjoy, and connect with industry influencers and peers at the luncheons, and after parties hosted by CWCBExpo on both the days.

Prominent members of the cannabis industry will share important insights, including:

Industry icon Josh Kesselman, Founder and CEO, of HBI International / RAW Rolling Papers, who will preside over the fireside chat/keynote speaker session.
Cy Scott, Co-Founder, CEO, of Headset, who will offer his insightful industry update on why New York is the next big cannabis market to watch out for and provide an update on rescheduling.

A special luncheon focusing on women in the cannabis business will be held on June 5, 2024. CWCBExpo is a leading B2B marketplace for networking within the cannabis community. Become a part of the interactive educational sessions, see unique product displays, participate in panel discussions, and seek the phenomenal opportunities offered by the CWCBExpo platform.

To learn more please visit https://cnw.fm/kVPAd & https://cnw.fm/O42wb.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Joins Others in Applauding Decision to Reschedule Cannabis

Company calls rescheduling a “monumental decision” that signifies a significant shift in U.S. drug policy
MedCana CEO notes rescheduling “opens the door to further research, innovation and accessibility, signaling a new era of acceptance and understanding”
SFWJ remains committed to advancing the dialogue around cannabis policy and supporting initiatives that promote responsible access and use

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) has noted a “historic milestone” as the U.S. Drug Enforcement Administration (“DEA”) moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (https://cnw.fm/yNude). The company released an announcement from CEO Jose Gabriel Diaz and observed that the “monumental decision,” based on recommendations from the U.S. Department of Health and Human Services, signifies a significant shift in U.S. drug policy.

“The DEA’s decision to reclassify cannabis is a watershed moment in our nation’s drug policy,” said Diaz. “It opens the door to further research, innovation and accessibility, signaling a new era of acceptance and understanding. MedCana is proud to be part of an industry that advocates for sensible cannabis regulation and equitable access to this vital medicine.”

MedCana joined many companies in responding to the proposed reclassification. “Many applauded the move to Schedule III from Schedule I, which the Associated Press first reported and was later confirmed by a Department of Justice spokesperson in a statement to Cannabis Business Times,” reported the Cannabis Business Times (https://cnw.fm/wW1WX). “Executives from plant-touching companies noted its significance as a historic step toward federal cannabis reform, destigmatization, fairer tax policies for businesses and more research into cannabis’s medical benefits.

“However, many also tempered the celebratory tone and said that there was much more work to be done,” the article continued. “Leaders from industry nonprofit organizations and some lawmakers emphasized their call for the federal government to deschedule cannabis altogether, something they urged after news circulated that the U.S. Department of Health and Human Services (‘HHS’) recommended that the DEA reschedule cannabis in August 2023.”

While there may be work left to do, the initial rescheduling is certainly noteworthy. The announcement from MedCana noted that cannabis has been unjustly categorized as a Schedule I substance alongside heroin and LSD for more than four decades. This was despite the fact that the substance has recognized medical benefits and low potential for abuse. The DEA’s move to reschedule cannabis — a move that will now undergo a period of public comment — is a clear indication of its therapeutic value and aligns with evolving attitudes toward cannabis policy.

In its announcement, MedCana stated that it remains committed to advancing the dialogue around cannabis policy and supporting initiatives that promote responsible use and access to quality cannabis products.

Operating under Software Effective Solutions Corp., MedCana is a pioneer in the integration of technology and agriculture, focusing on the cannabis market and emerging technologies in agriculture. With a vision to revolutionize the industry through innovation, MedCana is dedicated to acquiring and partnering with companies that align with its mission of promoting sustainable and technologically advanced agricultural practices.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Reports Indicate DEA Didn’t Support Marijuana Reclassification

In a secluded section of the U.S. Drug Enforcement Administration (DEA) headquarters known as the 12th-floor “bubble,” director Anne Milgram called a special “marijuana meeting” in March 2024 where she made an unusual request: no one was allowed to take notes. During the meeting, she informed her top deputies that the Biden administration was about to reschedule cannabis as a less-harmful substance, a significant move toward federal legalization that the agency has historically opposed.

Moreover, Milgram disclosed that this reclassification would be handled by the U. S. Department of Justice, not the DEA, and the final decision would be signed by Merrick Garland, the attorney general.

Milgram did not provide a reason for this unprecedented decision, and neither she nor the agency has done so subsequently. However, the plan unfolded exactly as she described, marking the most significant change in U.S. drug policy in half a century, without the DEA’s support.

The DEA has not yet determined the proper schedule for cannabis, according to a statement tucked on page 13 of Garland’s 92-page decision, which was released last Thursday. According to the order, cannabis would be moved from Schedule I, which is more restricted and contains narcotics such as LSD and heroin, to Schedule III, which is less restrictive and includes anabolic steroids and ketamine.

Internal documents show that the agency sent a memo to the DOJ in January, requesting more scientific data to determine if cannabis has approved medical use, a crucial factor for reclassification. However, DOJ attorneys overruled the DEA’s criteria, considering them too restrictive.

Several DEA officers, both past and present, indicated that political considerations could be driving this action. Rather than giving the DEA more time to carry out additional research, they think the DOJ is rushing the recategorization of marijuana to aid Biden in winning support from voters for his reelection campaign.

The DOJ’s engagement in the rescheduling process, in the opinion of retired DEA agent Derek Maltz, puts politics ahead of public safety. He underlined that such choices must be supported by scientific analysis.

Tim Shea, a former administrator of the DEA, echoed this statement, stating that Milgram’s absence from the signature shows her support for the DEA personnel. He voiced concern that the agency’s position had been overridden by political interference, which he said demoralized DEA staff.

The White House didn’t immediately respond, but it has said in the past that Biden is devoted to his pledge made during the campaign that no citizen should be imprisoned for marijuana use. DOJ attorneys supported Garland’s order, pointing out that it resulted from different perspectives held by the HHS and the DEA. Last year, HHS recommended rescheduling cannabis, considering it less harmful than drugs such as heroin and cocaine, and recognizing its effectiveness in treating conditions such as pain and anorexia.

Despite this recommendation, the DEA disagreed, citing the increasing potency of cannabis and the rise in emergency room visits due to its use. The DEA’s concerns were cited multiple times in Garland’s order. The DOJ, however, emphasized that it is legally bound to follow HHS’s medical and scientific determinations on drug classification.

The internal conflict highlights the ongoing debate over the risks of marijuana, despite 38 and 24 states legalizing it for medical and recreational use, respectively. Public support for legalization is also at an all-time high, with 70% of American adults in favor, according to a Gallup poll. Critics argue that the DEA’s stance is outdated and not aligned with public opinion.

The reclassification process, initiated by Biden’s 2022 order for a review, is expected to be lengthy. The DEA will take public comments on the proposal before an administrative judge reviews it and a final rule is published. While federal marijuana prosecutions are rare, its classification as a Schedule III drug would still subject it to regulation.

Milgram has not publicly discussed her position on cannabis. Known for her data-driven and progressive approach, she has historically viewed the legalization debate as less critical compared to the fentanyl crisis. Her recent brief announcement to DEA employees stated only that the agency would comply with posting the notice and attachments on its website, leaving her personal views on the matter unclear.

This revelation that the DEA wasn’t party to the recent announcement to reclassify marijuana federally may be of little consequence to the marijuana industry and its major actors such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) as the resulting policy change will require the compliance of all federal agencies.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

The Vermont Cannabis & Hemp Convention by NECANN to Generate Collaborative Deals for the Local Community

Entrepreneurs, traders, enthusiasts, patients, consumers, and service providers of the cannabis industry are invited to attend the Vermont Cannabis & Hemp Convention, a pioneering B2B cannabis industry event on the East Coast. Engaged in organizing conventions since 2014, NECANN believes in bringing together the local cannabis community for better growth and business prospects. The event features the expo, workshops, and programming tracks, in addition to speaker sessions and panel discussions by industry experts. The age limit to attend the conference is 21+.

The NECANN team comprises a group of passionate and talented professionals who design an extensive agenda that involves two days of robust learning, exploration, and networking. The attendees can connect with investors and peers for collaborations and a higher ROI. New businesses as well as seasoned traders exhibit their innovative products and services to leverage the expensive reach of the NECANN platform.

Investors and businesses looking for fresh areas of investment can discover new and exciting products at the exhibition booths. NECANN is a profitable forum for the local community of cultivators, growers, traders, and businesses in Vermont and New England vicinity. The networking connections developed at the NECANN convention will help local retailers expand their reach to earn new businesses and customers.

The convention will feature an impressive line of industry leaders who preside over the speaker sessions at the summit. They will offer their priced insights and strategies on the latest trends in the market. The experts will also talk about the role of AI in shaping consumer experience, the latest regulations, and several other topics of importance. Attendees can customize their schedule and only their bookmarked events.

To know more, please visit https://cnw.fm/S0s5u.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH), Subsidiary Focused on Becoming Leaders in Sector Projected to See Billion-Dollar Growth

Recent report notes that the U.S. conferences, concert and event market is on a trajectory of remarkable growth
A driving force behind the rapid growth is an increasing demand for unique, immersive experiences
Lavish Entertainment is building a reputation for producing high-quality, professional events that offer memorable experiences

With a recent analyst report projecting significant growth in the U.S. conferences, concert and event market, Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, are strengthening their strategic position in the space at an ideal time.

“The United States conferences, concert and event market is on a trajectory of remarkable growth, projected to reach an impressive $660.07 billion by the year 2030,” reported the latest ResearchandMarkets.com report for the industry (https://cnw.fm/wLX9o). The space reportedly reached $339.86 billion in 2022 and is forecast to see a CAGR of 8.65% from 2022 to 2030.

“This sector is currently witnessing a revolutionary phase, with unprecedented developments and transformative changes,” the report continued. “Events have become powerful platforms that bring people together for various purposes, including corporate development, entertainment, celebration, and community engagement. From conferences and business seminars to fundraisers, music performances, sports events, festivals, trade exhibitions, and product launches, a wide array of events are immensely popular across the nation. . . .

“The conference, concert and event sector in the United States is vibrant and diverse, comprising a multitude of activities catering to diverse interests and demographics,” the report stated. “Beyond just entertainment, this industry plays a crucial role in fostering economic development, generating wealth and creating employment opportunities.”

ResearchandMarkets.com noted that a significant driving force behind the space’s rapid growth is an increasing demand for unique and immersive experiences. Event organizers continuously strive to innovate and exceed boundaries to provide fascinating interactions for attendees. “From interactive exhibitions and immersive marketing activations to live performances and gourmet experiences, events are designed to amaze and engage people in extraordinary ways. As the thirst for exceptional experiences grows, the events market in the United States is set to flourish in the coming years.”

Exceptional events are exactly what Lavish Entertainment is dedicated to providing. A wholly owned subsidiary of Golden Triangle Ventures, Lavish Entertainment is currently headquartered in Las Vegas and is committed to producing high-quality, professional events that provide immersive, memorable experiences (https://cnw.fm/EJWX3). In addition to becoming nationally recognized in concert production, the company is currently developing a flagship entertainment complex called Destino Ranch, an outdoor music and festival venue, immersive art installation, tourist attraction, and destination center — all in one location.

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, as well as in other areas that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Research Hurdles Could Remain Despite Federal Rescheduling

The Biden administration’s decision to reclassify cannabis as a less-harmful drug might ease some research challenges, though scientists caution that obstacles will persist. Ziva Cooper, director of the UCLA Center for Marijuana and Cannabinoids, described this moment as historically significant but expressed cautious optimism about the actual implementation of these changes.

Although many Americans now live in states where marijuana is legal, federal restrictions have historically constrained research into its effects and applications. Researchers who have long studied marijuana believe this reclassification could boost funding and interest in research. However, they acknowledge that regulatory and logistical issues may still dampen enthusiasm.

Traci Toomey, who heads the University of Minnesota’s Marijuana Research Center, echoed Cooper’s sentiments. She noted that while some research opportunities might open up, these opportunities will not be entirely unrestricted.

Last week, the U.S. Department of Justice formally recommended reclassifying cannabis as a Schedule III substance, which recognizes its potential medical benefits and aligns its classification with drugs such as codeine-infused Tylenol, testosterone and ketamine. This shift would not legalize cannabis at the federal level but would remove it from the same category as LSD and heroin, thus reducing some of the restrictions around it.

Recently, an assessment by the U.S. Department of Health and Human Services noted that there was some reliable scientific evidence supporting the use of cannabis as a treatment for specific ailments. Nonetheless, some detractors contend that there is insufficient proof to support its medicinal application.

The federal government’s finalization of this reclassification will probably lower certain barriers to study. It will be easier for academics to obtain federal research licenses, and researchers won’t need to store cannabis in costly, highly secure facilities. Moreover, the U.S. Drug Enforcement Administration would no longer impose quotas on cannabis production for research purposes.

This could make hospitals, universities and even government agencies more willing to support clinical trials involving marijuana, according to Will Humble, executive director of the Arizona Public Health Association.

However, the impact of FDA regulations on cannabis research remains uncertain. While the FDA normally approves Schedule III drugs, it has not yet approved cannabis for any treatment, although it is commonly used for pain treatment, hunger stimulation and nausea control following chemotherapy.

Furthermore, rescheduling marijuana will not immediately increase the number of FDA-approved facilities where researchers can obtain the drug.

Valerie Ahanonu, head of the University of Utah’s Center for Medical Marijuana Research, highlighted that even years after the legalization of hemp-derived CBD, research remains difficult due to sourcing issues that meet federal standards. Ahanonu stressed the complexity and extensive bureaucratic procedures involved, making it uncertain how much the reclassification will genuinely enhance research opportunities.

Despite these challenges, the potential for expanded research and a greater understanding of marijuana’s medical applications remains promising, and marijuana enterprises such as Aurora Cannabis Corp. (NASDAQ: ACB) (TSX: ACB) are likely to applaud every policy change that moves cannabis a step away from the existing prohibitive restrictions at the federal level.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com